Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 4/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28211238 | 0.87 | GABRA1 (0.45) | GABRA1GABRB2CYP3A4PARP1TDP1 | |
| SCHEMBL29648839 | 0.84 | GABRA1 (0.46) | GABRA1GABRB2CYP3A4TRPA1TDP1 | |
| SCHEMBL1456973 | 0.84 | GABRA1 (0.46) | GABRA1GABRB2CYP3A4TRPA1TDP1 | |
| SCHEMBL7528335 | 0.83 | CYP3A4 (0.45) | GABRA1GABRB2CYP3A4ARTRPA1 | |
| SCHEMBL374209 | 0.80 | GABRA1 (0.56) | GABRA1GABRB2CYP3A4TRPA1TDP1 | |
| SCHEMBL158739 | 0.80 | GABRA1 (0.40) | GABRA1GABRB2CYP3A4ARPARP1 | |
| SCHEMBL21958796 | 0.79 | ATM (0.39) | GABRA1GABRB2CYP3A4ARPARP1 | |
| SCHEMBL10613040 | 0.79 | GABRA1 (0.68) | GABRA1GABRB2CYP3A4ARPARP1 | |
| SCHEMBL163538 | 0.79 | GABRA1 (0.43) | GABRA1GABRB2CYP3A4ARPARP1 | |
| SCHEMBL8093597 | 0.76 | CYP3A4 (0.47) | CYP3A4ARTRPA1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2104665-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| WO-2008046758-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| EP-0217787-A4 | AMIDINOUREA PROCESS AND PHARMACEUTICAL COMPOSITION. | RORER INTERNAT OVERSEAS INC (US) | 1988-07-21 | — | — | EP | disclosed |
| EP-0217787-A1 | AMIDINOUREA PROCESS AND PHARMACEUTICAL COMPOSITION | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1987-04-15 | — | — | EP | disclosed |
| WO-1986004935-A1 | AMIDINOUREA PROCESS AND PHARMACEUTICAL COMPOSITION | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1986-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HSD11B1, HSD17B1, HSD17B11 | GABRA1 1345/4885GABRB2 1591/4885CYP3A4 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.